Cargando…
Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198409/ https://www.ncbi.nlm.nih.gov/pubmed/32380318 http://dx.doi.org/10.1016/j.autrev.2020.102563 |
| _version_ | 1783528977732730880 |
|---|---|
| author | Cunningham, Louise Kimber, Ian Basketter, David Arthur McFadden, John Paul |
| author_facet | Cunningham, Louise Kimber, Ian Basketter, David Arthur McFadden, John Paul |
| author_sort | Cunningham, Louise |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7198409 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-71984092020-05-05 Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection Cunningham, Louise Kimber, Ian Basketter, David Arthur McFadden, John Paul Autoimmun Rev Article Elsevier B.V. 2020-07 2020-05-05 /pmc/articles/PMC7198409/ /pubmed/32380318 http://dx.doi.org/10.1016/j.autrev.2020.102563 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Cunningham, Louise Kimber, Ian Basketter, David Arthur McFadden, John Paul Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection |
| title | Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection |
| title_full | Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection |
| title_fullStr | Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection |
| title_full_unstemmed | Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection |
| title_short | Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection |
| title_sort | why judiciously timed anti-il 6 therapy may be of benefit in severe covid-19 infection |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198409/ https://www.ncbi.nlm.nih.gov/pubmed/32380318 http://dx.doi.org/10.1016/j.autrev.2020.102563 |
| work_keys_str_mv | AT cunninghamlouise whyjudiciouslytimedantiil6therapymaybeofbenefitinseverecovid19infection AT kimberian whyjudiciouslytimedantiil6therapymaybeofbenefitinseverecovid19infection AT basketterdavidarthur whyjudiciouslytimedantiil6therapymaybeofbenefitinseverecovid19infection AT mcfaddenjohnpaul whyjudiciouslytimedantiil6therapymaybeofbenefitinseverecovid19infection |